Kerostx
Founded 2016 · 125 employees on LinkedIn · 2 known investors
Keros Therapeutics develops therapies targeting the transforming growth factor-beta (TGF-ß) family of proteins to treat disorders linked to dysfunctional TGF-ß signaling. The company focuses on innovative treatments for patients with a range of such disorders.
Investors · 2
Frequently asked questions
- What does Kerostx do?
- Keros Therapeutics develops therapies targeting the transforming growth factor-beta (TGF-ß) family of proteins to treat disorders linked to dysfunctional TGF-ß signaling. The company focuses on innovative treatments for patients with a range of such disorders.
- Who are Kerostx's investors?
- Kerostx's investors include OrbiMed, Pontifax Venture Capital.